F S&P 500
4,996.75 -52.25 (-1.03%) F Dow Jones
37,656.00 -351.00 (-0.92%) F Nasdaq
17,322.25 -225.00 (-1.28%) E-mini Russell 2000 Index Futur
1,933.50 -24.60 (-1.26%) Petróleo
85.18 +2.45 (+2.96%) Oro
2,406.30 +8.30 (+0.35%)
Alkermes plc (ALKS)
Fuera de horario:
Alkermes plc
Connaught House
1 Burlington Road Dublin 4
Dublin D04 C5Y6
Ireland
353 1 772 8000
https://www.alkermes.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 2,100
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Richard F. Pops | Chairman & CEO | 2.3M | 5.15M | 1962 |
| Mr. David Joseph Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 1.08M | N/D | 1972 |
| Mr. Iain Michael Brown | Senior VP & CFO (Leave of Absence) | 867.75k | N/D | 1969 |
| Dr. Craig C. Hopkinson M.D. | Executive VP of Research & Development and Chief Medical Officer | 1.12M | N/D | 1968 |
| Dr. Floyd E. Bloom M.D. | Founder | 57.73k | N/D | 1937 |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & VP of Finance | N/D | N/D | 1975 |
| Mr. Thomas Harvey | Chief Information Officer & Senior VP of IT | N/D | N/D | N/D |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | N/D | N/D | N/D |
| Mr. Stephen Schiavo | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Mr. Peter Norman | Senior Vice President of Policy & Government Relations | N/D | N/D | N/D |
Descripción
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Gestión corporativa
La calificación ISS Governance QuickScore de Alkermes plc a partir del 1 de abril de 2024 es 3. Las puntuaciones principales son Auditoría: 1; Junta: 6; Derechos del accionista: 3; Compensación: 4.
